C7

C7 is a designation assigned to chemically distinct preclinical lead compounds identified in independent pharmacological studies. In the context of pulmonary oncology, C7 is a small molecule inhibitor of Matrix Metalloproteinase-12 (MMP12) that has demonstrated efficacy in suppressing non-small cell lung cancer (NSCLC) cell migration, perturbing the cell cycle, and inducing apoptosis. In a separate research context focused on cardiovascular protection, C7 refers to a hybrid derivative of the triterpenoid saponin Calenduloside E (CE) covalently linked to a ticagrelor-derived fragment. This version of C7 targets Heat Shock Protein 90 beta (HSP90β) and the P2Y12 receptor, exhibiting protective activity against oxidized low-density lipoprotein (ox-LDL)-induced injury in human umbilical vein endothelial cells (HUVECs). Both iterations of C7 are currently in early-stage research for the treatment of lung cancer and atherosclerosis, respectively.